Patient characteristics
Twenty-one patients with CVID (14 women and 7 men) were enrolled in the
study. The mean age was 46.3 years (±9.7 SD). The mean disease duration
was 9.1 years (±7.49). All patients underwent regular IRT with
intravenous (IVIG: 23.8%, n=5/21) or subcutaneous (SCIG: 76.2%,
n=16/21) administration, with mean dose of 287.6 mg/kg/month (± 69.6).
The mean serum IgG trough level was 6.13 g/L (±1.59). Antibiotic
prophylaxis was indicated in three patients with CVID (14.3%),
including cotrimoxazole and macrolides. Non-infectious complications
were observed in 16 patients (76.2%), and the most prevalent
complications were bronchial asthma (28.6%, n=6/21), autoimmune
thyroiditis (23.8%, n=5/21), enteropathy (23.8%, n=5/21), chronic lung
disease (19%, n=4/21), splenomegaly (19%, n=4/21), vitiligo (19%,
n=4/21), immune thrombocytopenic purpura (9.5%, n=2/21),
lymphadenopathy (9.5%, n=2/21), and sarcoid-like disease (9.5%,
n=2/21). Other complications were present in <2 patients, and
6 patients exhibited >2 complications. Three patients
(14.3%) were on active immunosuppression with glucocorticosteroids upon
vaccination, and five (23.8%) had previously received immunosuppressive
therapy. Patient characteristics are summarized in Table 1.